Adalimumab-adbm injection, a biosimilar to Humira ® (adalimumab), has been made available by Boehringer Ingelheim. Adalimumab-adbm injection is an interchangeable biosimilar and can be substituted for ...

Tennessee last year spent $48 million on a single drug, Humira — about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment. So ...

Several biosimilars for the world’s top-selling drug are slated to hit the market next year, but the potential billions of dollars in savings may not materialize until at least 2024. Humira, the ...

Aug. 22, 2005 — The European Commission has approved adalimumab subcutaneous injection for the treatment of psoriatic arthritis and as first-line therapy for severe, active, and progressive rheumatoid ...

Even through an onslaught of biosimilar launches that began early last year, AbbVie’s big-selling Humira has been able to retain most of its lucrative market. Still, though, the drug’s star power is ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. (Bloomberg) — AbbVie Inc. doesn’t foresee an earnings ...

A long-awaited moment for consumers arrived last year when patent protection expired on the nation’s most prescribed medicine, AbbVie’s wildly successful — and costly — rheumatoid arthritis drug ...

Please provide your email address to receive an email when new articles are posted on . Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just ...

Humira (adalimumab) has potential interactions with several other drugs. For example, taking prednisone with Humira can increase the risk of side effects from both drugs. Humira may also interact with ...